• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Acamprosate, naltrexone may be effective for alcoholic disorders

byAshmita BanerjeeandBrittany Hasty, MD
May 14, 2014
in Chronic Disease
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

Image: PD 

1. Oral acamprosate and naltrexone, together with psychosocial interventions, were linked with an improvement in return to any drinking. Naltrexone was linked to reductions in return to heavy drinking. 

2. No significant association were found with the health outcomes and adverse effects for either of the drugs. 

Evidence Rating Level: 2 (Good)  

Study Rundown: Alcohol use disorders (AUDs) are infrequently treated with medications. This is an area of high concern because of the significant morbidity and mortality associated with AUDs. This study found that both acamprosate and oral naltrexone, combined with psychosocial interventions, are effective for reducing consumption outcomes: both drugs are associated with abstinence but only naltrexone was linked to improvement in return to heavy drinking. None of these two or other drugs tested, which included disulfiram and several other off-label medications, showed any significant association with improvement in health outcomes (motor vehicle accidents, injuries, quality of life, function and mortality). Although the U.S. Preventive Services Task Force (USPSTF) recommends primary care screening of alcohol misuse, the study found very little evidence to back this recommendation upon analysis of studies in primary care settings. This systematic review and meta-analysis has significant limitations. The concomitant psychosocial interventions used were not defined or taken into consideration for analysis. No comparisons were made between pharmacological interventions and psychosocial outcomes alone. Moreover, randomized control trials (RCTs) analyzed for acamprosate and naltrexone showed a preponderance of European trials and US-based trials, respectively, with differences in patient recruitment based on location.

Click to read the study, published today in JAMA

RELATED REPORTS

Evidence gap for acute pain outcomes in opioid use disorder

The Scan by 2 Minute Medicine®: Another Viral Virus, Is One Drink Too Much?, Eggs, Humans, and the Flu, and Detrimental Exercise:

Certain genetic predispositions may increase risk of atrial fibrillation among those with high alcohol consumption

Relevant Reading: Acamprosate supports abstinence, Naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes

In-Depth [systematic review and meta-analysis]: This study included 123 articles that looked at pharmacotherapy combined with psychosocial interventions in outpatient settings for patients with verifiable AUDs. This study found no significant difference between acamprosate and naltrexone in consumption outcomes. For return to heavy drinking, only oral naltrexone (50 mg/d) was associated with improvement with an NNT of 12 (95% CI; 8 to 26; 19 trials; n = 2875). Insufficient evidence for association of injectable naltrexone and disulfiram with improvement in any of the alcohol consumption outcomes was noted. In addition, there was insufficient evidence for improvement in any of the health outcomes including motor vehicle accidents, injuries, quality of life, function and mortality. Finally, post hoc subgroup analysis by risk of bias for acamprosate versus placebo showed a decreasing effect size from high risk of bias (RD, – 0.13, 95% CI, – 0.2 to – 0.06) to low risk (RD, – 0.02, 95% CI, – 0.09 0.05) for improvement in returning to any drinking.

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: AcamprosateAlcoholNaltrexone
Previous Post

PET-CT no better than CT for pre-op planning in liver metastases of colorectal cancer

Next Post

New drug for Chagas disease shows antitrypanosomal activity [CHAGASAZOL trial]

RelatedReports

Parental nonmedical prescription opioid use linked to adolescent use
Pharma

Evidence gap for acute pain outcomes in opioid use disorder

March 24, 2025
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Another Viral Virus, Is One Drink Too Much?, Eggs, Humans, and the Flu, and Detrimental Exercise:

January 21, 2025
Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source
Cardiology

Certain genetic predispositions may increase risk of atrial fibrillation among those with high alcohol consumption

December 29, 2023
Greater prenatal alcohol exposure trajectories linked to impaired growth and neurodevelopment
Cardiology

Infrequent and light alcohol consumption are still associated with poorer health outcomes

June 16, 2023
Next Post
New drug for Chagas disease shows antitrypanosomal activity [CHAGASAZOL trial]

New drug for Chagas disease shows antitrypanosomal activity [CHAGASAZOL trial]

Low circulating cholesterol in neonates linked with pyloric stenosis

Adding Evolocumab to statin therapy further decreases LDL-C levels

Rhinovirus, genes may interact to increase the risk of childhood asthma

Link between early life antibiotic use, asthma exacerbations, and impaired viral immunity

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Breast cancer survivors may have a lower risk of Alzheimer’s dementia
  • Evaluating scar outcomes in pediatric burn patients following skin grafting 
  • Novel inhibitory antibody, MAR001, lowers triglycerides and remnant cholesterol in humans
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.